---
title: "TransThera reports promising tinengotinib results in advanced solid tumors"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286670762.md"
description: "TransThera Sciences (Nanjing) has reported promising results for its multi-kinase inhibitor tinengotinib in advanced solid tumors. In a phase Ib/II study, tinengotinib achieved objective response rates of 16.7% as a monotherapy and 22.6% in combination with atezolizumab, particularly effective in cholangiocarcinoma patients. The drug demonstrated efficacy in FGFR2 fusion cases resistant to prior treatments, supporting further clinical development."
datetime: "2026-05-17T11:07:33.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286670762.md)
  - [en](https://longbridge.com/en/news/286670762.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286670762.md)
---

# TransThera reports promising tinengotinib results in advanced solid tumors

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

An update from TransThera Sciences (Nanjing). Inc. ( (HK:2617) ) is now available.

TransThera Sciences (Nanjing) has reported new clinical data for its spectrum-selective multi-kinase inhibitor tinengotinib, targeting FGFR1-3, JAK1/2, VEGFRs and Aurora A/B, in patients with advanced solid tumors. The phase Ib/II study, conducted in China, evaluated tinengotinib both as a monotherapy and in combination with the immunotherapy agent atezolizumab.

Tinengotinib achieved objective response rates of 16.7% as a standalone treatment and 22.6% when combined with atezolizumab, with particularly strong results in cholangiocarcinoma patients. The drug showed notable efficacy in cases with FGFR2 fusion that had progressed on prior FGFR inhibitors, and the combination regimen delivered meaningful disease control in patients previously treated with immune checkpoint inhibitors, supporting continued clinical development of the asset.

**More about TransThera Sciences (Nanjing). Inc.**

TransThera Sciences (Nanjing), Inc. is a China-based biopharmaceutical company focused on developing innovative targeted therapies for solid tumors. Listed in Hong Kong, the company is advancing a pipeline of kinase inhibitors and immunotherapy combinations aimed at difficult-to-treat cancers such as cholangiocarcinoma and other advanced solid tumors.

**Average Trading Volume:** 2,500,535

**Technical Sentiment Signal:** Strong Sell

**Current Market Cap:** HK$15B

See more data about 2617 stock on TipRanks’ Stock Analysis page.

### Related Stocks

- [159992.CN](https://longbridge.com/en/quote/159992.CN.md)
- [520500.CN](https://longbridge.com/en/quote/520500.CN.md)
- [512290.CN](https://longbridge.com/en/quote/512290.CN.md)
- [159570.CN](https://longbridge.com/en/quote/159570.CN.md)
- [159316.CN](https://longbridge.com/en/quote/159316.CN.md)
- [516500.CN](https://longbridge.com/en/quote/516500.CN.md)
- [510660.CN](https://longbridge.com/en/quote/510660.CN.md)
- [159892.CN](https://longbridge.com/en/quote/159892.CN.md)
- [520880.CN](https://longbridge.com/en/quote/520880.CN.md)
- [516930.CN](https://longbridge.com/en/quote/516930.CN.md)
- [159849.CN](https://longbridge.com/en/quote/159849.CN.md)
- [520690.CN](https://longbridge.com/en/quote/520690.CN.md)
- [513120.CN](https://longbridge.com/en/quote/513120.CN.md)
- [159748.CN](https://longbridge.com/en/quote/159748.CN.md)
- [512010.CN](https://longbridge.com/en/quote/512010.CN.md)
- [562050.CN](https://longbridge.com/en/quote/562050.CN.md)
- [588130.CN](https://longbridge.com/en/quote/588130.CN.md)
- [159506.CN](https://longbridge.com/en/quote/159506.CN.md)
- [513700.CN](https://longbridge.com/en/quote/513700.CN.md)
- [159837.CN](https://longbridge.com/en/quote/159837.CN.md)
- [513060.CN](https://longbridge.com/en/quote/513060.CN.md)
- [02617.HK](https://longbridge.com/en/quote/02617.HK.md)

## Related News & Research

- [20:03 ETHarbour BioMed Announces Promising Preclinical Data for LET003, Its First AI-Enabled Drug Candidate](https://longbridge.com/en/news/286688082.md)
- [Analyst Reiterates Buy on Microbix, Citing Temporary China Slowdown and Growing Diversified Demand](https://longbridge.com/en/news/286665358.md)
- [Leads Biolabs R&D Symposium: Platform Synergy and Multi-Mechanism Integration Reshape the Immuno-Oncology Landscape](https://longbridge.com/en/news/285930281.md)
- [Everest Medicines Director and Major Shareholder Raises Stake in Company](https://longbridge.com/en/news/286481551.md)
- [Wuxi AppTec to Raise Around $1 Billion Through Zero Coupon Convertible Bonds](https://longbridge.com/en/news/286487023.md)